Araz Marachelian

1.9k total citations
54 papers, 943 citations indexed

About

Araz Marachelian is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, Araz Marachelian has authored 54 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Neurology, 22 papers in Molecular Biology and 20 papers in Cancer Research. Recurrent topics in Araz Marachelian's work include Neuroblastoma Research and Treatments (44 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Cancer therapeutics and mechanisms (17 papers). Araz Marachelian is often cited by papers focused on Neuroblastoma Research and Treatments (44 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Cancer therapeutics and mechanisms (17 papers). Araz Marachelian collaborates with scholars based in United States, Canada and Australia. Araz Marachelian's co-authors include Katherine K. Matthay, Judith G. Villablanca, Rima Jubran, Susan Groshen, John M. Maris, Fariba Goodarzian, Jonathan L. Finlay, Denice Tsao‐Wei, Marcio H. Malogolowkin and Hiroyuki Shimada and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Araz Marachelian

52 papers receiving 934 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Araz Marachelian United States	17	475	379	221	187	182	54	943
Kenneth B. DeSantes United States	16	374 0.8×	275 0.7×	175 0.8×	108 0.6×	109 0.6×	32	1.1k
Stephen S. Roberts United States	20	743 1.6×	508 1.3×	303 1.4×	126 0.7×	75 0.4×	73	1.3k
Loretta M. S. Lau Australia	21	259 0.5×	593 1.6×	148 0.7×	119 0.6×	116 0.6×	52	1.3k
Renato Mastrangelo Italy	21	415 0.9×	313 0.8×	238 1.1×	259 1.4×	160 0.9×	57	1.2k
E. Stanton Adkins United States	8	687 1.4×	455 1.2×	242 1.1×	79 0.4×	138 0.8×	13	895
Meaghan Granger United States	12	337 0.7×	256 0.7×	180 0.8×	55 0.3×	46 0.3×	33	620
Nathan Robison United States	16	349 0.7×	270 0.7×	85 0.4×	572 3.1×	53 0.3×	49	969
Mara Albonei Dudeque Pianovski Brazil	15	178 0.4×	259 0.7×	469 2.1×	200 1.1×	592 3.3×	38	990
Adam L. Green United States	19	153 0.3×	376 1.0×	91 0.4×	283 1.5×	45 0.2×	55	923
Aurora Navajas Spain	18	205 0.4×	380 1.0×	175 0.8×	239 1.3×	51 0.3×	41	1.1k

Countries citing papers authored by Araz Marachelian

Since Specialization

Citations

This map shows the geographic impact of Araz Marachelian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Araz Marachelian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Araz Marachelian more than expected).

Fields of papers citing papers by Araz Marachelian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Araz Marachelian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Araz Marachelian. The network helps show where Araz Marachelian may publish in the future.

Co-authorship network of co-authors of Araz Marachelian

This figure shows the co-authorship network connecting the top 25 collaborators of Araz Marachelian. A scholar is included among the top collaborators of Araz Marachelian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Araz Marachelian. Araz Marachelian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hogarty, Michael D., David S. Ziegler, Andrea Franson, et al.. (2024). Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. British Journal of Cancer. 130(5). 788–797. 10 indexed citations

Desai, Ami V., Arlene Naranjo, Kelly C. Goldsmith, et al.. (2024). A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.. Journal of Clinical Oncology. 42(16_suppl). 10004–10004. 1 indexed citations

Kaye, Erica C., Jesse Smith, Yiwang Zhou, et al.. (2023). Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi‐site longitudinal survey study. Cancer. 130(7). 1101–1111. 6 indexed citations

Batra, Vandana, Ajami Gikandi, Bruce Pawel, et al.. (2023). Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to ¹³¹I‐MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. 71(1). e30743–e30743. 2 indexed citations

Nysom, Karsten, et al.. (2023). Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus. Pediatric Blood & Cancer. 70(5). e30217–e30217. 5 indexed citations

Keens, Thomas G., et al.. (2023). Congenital central hypoventilation syndrome without hypoventilation: is it congenital central hypoventilation syndrome?. Journal of Clinical Sleep Medicine. 19(6). 1161–1164. 1 indexed citations

Asgharzadeh, Shahab, Araz Marachelian, Judith G. Villablanca, et al.. (2022). Expression of neuroblastoma‐related genes in bone marrow at end of high‐risk neuroblastoma therapy. Pediatric Blood & Cancer. 69(9). e29719–e29719. 3 indexed citations

Cash, Thomas F., Araz Marachelian, Steven G. DuBois, et al.. (2022). Phase I study of ¹³¹I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.. Journal of Clinical Oncology. 40(16_suppl). 10038–10038. 2 indexed citations

Federico, Sara M., Arlene Naranjo, Fan Zhang, et al.. (2022). A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. Journal of Clinical Oncology. 40(16_suppl). 10003–10003. 8 indexed citations

10.

Goodarzian, Fariba, et al.. (2020). Premature epiphyseal growth plate arrest after isotretinoin therapy for high‐risk neuroblastoma: A case series and review of the literature. Pediatric Blood & Cancer. 67(8). e28236–e28236. 6 indexed citations

11.

Zobel, Michael J., et al.. (2020). The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors. Journal of Surgical Research. 249. 8–12. 3 indexed citations

12.

Mack, Jennifer W., Angel M. Cronin, Hajime Uno, et al.. (2019). Unrealistic parental expectations for cure in poor‐prognosis childhood cancer. Cancer. 126(2). 416–424. 38 indexed citations

13.

Villablanca, Judith G., Lingyun Ji, Araz Marachelian, et al.. (2018). Predictors of response, progression‐free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high‐risk neuroblastoma. Pediatric Blood & Cancer. 65(5). e26940–e26940. 7 indexed citations

14.

Pinto, Navin, Steven G. DuBois, Araz Marachelian, et al.. (2018). Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood & Cancer. 65(7). e27023–e27023. 27 indexed citations

15.

Tran, Hung C., Araz Marachelian, Rajkumar Venkatramani, Rima Jubran, & Leo Mascarenhas. (2014). Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma. Pediatric Hematology and Oncology. 32(1). 26–31. 14 indexed citations

16.

Marachelian, Araz, Hiroyuki Shimada, Hideki Sano, et al.. (2011). The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatric Blood & Cancer. 58(5). 675–681. 21 indexed citations

17.

Russell, Heidi V., Susan Groshen, Tasnim Ara, et al.. (2010). A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study. Pediatric Blood & Cancer. 57(2). 275–282. 39 indexed citations

18.

Wong, Kenneth, et al.. (2009). Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex. Pediatric Blood & Cancer. 54(1). 170–172. 2 indexed citations

19.

Russell, Heidi V., Yves A. DeClerck, Takahide Ara, et al.. (2009). A phase I study of zoledronic acid (ZA) and low-dose cyclophosphamide (CTX) in children with recurrent/refractory neuroblastoma (NB): A New Approaches to Neuroblastoma Therapy (NANT) study. Journal of Clinical Oncology. 27(15_suppl). 10022–10022. 1 indexed citations

20.

Marachelian, Araz, A Butturini, & Jonathan L. Finlay. (2008). Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transplantation. 41(2). 167–172. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact